Vis enkel innførsel

dc.contributor.authorØvrebø, Bente
dc.contributor.authorStrømmen, Magnus
dc.contributor.authorKulseng, Bård Eirik
dc.contributor.authorMartins, Catia
dc.date.accessioned2018-02-23T13:28:58Z
dc.date.available2018-02-23T13:28:58Z
dc.date.created2017-03-30T19:03:40Z
dc.date.issued2017
dc.identifier.citationClinical Obesity. 2017, 7 (3), 183-190.nb_NO
dc.identifier.issn1758-8111
dc.identifier.urihttp://hdl.handle.net/11250/2486786
dc.description.abstractChanges in body weight (BW), risk factors and comorbidities 5 years after Roux-en-Y gastric bypass (RYGB) or different lifestyle interventions are compared. A total of 209 (75% women) severe obese adults were non-randomly allocated to: (A) RYGB (n = 58), (B) weight loss (WL) camp (n = 30), (C) residential intermittent programme (n = 64) or (D) hospital outpatient programme (n = 57). Body weight, risk factors and comorbidities were assessed at baseline, 1 and 5 years. A total of 89 and 54% completed the 1- and 5-year follow-up. The RYGB group experienced more WL at 5 years (−23.9%, 95% CI [−27.7, −20.0]) compared with lifestyle groups: (B) (−9.2%, 95% CI [−16.9, −1.5]), (C) (−4.1%, 95% CI [−8.0, −0.1]) and (D) (−4.1 kg, 95% CI [−10.0, 1.8]) (all P < 0.001). No differences were observed between lifestyle groups, although groups B and C had significant WL after 5 years (all P < 0.05). Plasma glucose and high-density lipoprotein cholesterol were improved in the RYGB group at 5 years compared with lifestyle groups (all P < 0.05). More patients in the RYGB group experienced remission of hypertension (P < 0.05). RYGB was associated with a lower BW, improved blood parameters and hypertension remission compared with lifestyle interventions at 5 years. However, significant WL was also achieved with lifestyle interventions.nb_NO
dc.language.isoengnb_NO
dc.publisherWileynb_NO
dc.titleBariatric surgery versus lifestyle interventions for severe obesity: 5-year changes in body weight, risk factors and comorbiditiesnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionacceptedVersionnb_NO
dc.source.pagenumber183-190nb_NO
dc.source.volume7nb_NO
dc.source.journalClinical Obesitynb_NO
dc.source.issue3nb_NO
dc.identifier.doi10.1111/cob.12190
dc.identifier.cristin1462554
dc.description.localcode© 2017 World Obesity Federation. This is the peer reviewed version of the article, locked until 20 March 2018 due to copyright restrictions. It has been published in final form at http://dx.doi.org/10.1111/cob.12190. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.nb_NO
cristin.unitcode194,65,15,0
cristin.unitcode194,65,30,0
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.unitnameInstitutt for nevromedisin og bevegelsesvitenskap
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel